Novem Group Halozyme Therapeutics, Inc. Transaction History
Novem Group
- $713 Billion
- Q1 2025
A detailed history of Novem Group transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Novem Group holds 22,407 shares of HALO stock, worth $1.38 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
22,407
Previous 17,586
27.41%
Holding current value
$1.38 Million
Previous $841 Million
70.05%
% of portfolio
0.2%
Previous 0.12%
Shares
2 transactions
Others Institutions Holding HALO
# of Institutions
566Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.08 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$816 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$441 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$256 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$212 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.56B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...